#EAPM: Last registration days for cutting-edge conference on personalised medicine

Time is running out to register for the fifth annual European Alliance for Personalised Medicine conference, to be held in Brussels on 28 March.

The final date for registration is 23 March.

While the conference, entitled ‘Innovation, Guidelines and Screening: The Case of Lung Cancer’ will take a close look at lung-cancer screening, its general subject matter will be much broader than that, focusing on many of the issues that affect personalised medicine today.

European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan said of the event, which will take place at the prestigious Bibliothèque Solvay: “This conference will be interactive and innovative. In these fast-changing times in the world of medicine, with all the incredible new science, we need a clear voice from the health and research community to shake-up the area and get all other aspects - such as regulation, cooperation and integration into healthcare systems - moving at a faster pace to keep up with the technology.”

He added: “The main thrust of the meeting will not be about just one disease, but more the issues surrounding governance - whether EU-wide, national or regional - discussed by experts and all stakeholder groups.”

These groups will be examining the need for more recommendations and guidelines on health and preventative measures across the current 28 member states, affecting some 500 million EU citizens.

In that respect, the conference will focus on a broad range of issues and diseases, albeit with lung cancer at the centre (as it is the biggest killer of all cancers).

Key conference themes are:

• Generating alignment in the area of diagnosis: Development of guidelines
• Securing patient access to better care through screening guidelines
• Screening and mapping from other disease areas: Learning and sharing.

Please click here to see the updated agenda. Key to the conference will be the issues surrounding how health care is governed in the EU and what influence, in effect, Brussels can and does have, bearing in mind that much of the areas of health come under member state competence (although Europe has stepped up of late in areas such as clinical trials and IVDs). New, up-to-date guidelines (on screening and more) would be one way forward, given that they potentially have less rigidity and therefore more flexibility (within strict standards of safety and ethics, of course).

Added EAPM’s Horgan: “We can clearly see that innovation has brought about a greater need for adaptation through appropriate frameworks that must be designed by experts, in consensus - albeit with plenty of necessary input from regulatory bodies.”

“It is vital to ensure that any and all agreed standards can be met down the line. Our conference aims to provide a great start to that process,” he said.

To register, please click here.

Share this article: